Kindheitsimpfplan

Vaccination is carried out after the vaccination plan of the Center for “Disease Control and Prevention,” the “AAP” and the “American Academy of Family Physicians” (see table: Recommended vaccination schedule for the age of 0-6 years, recommended vaccination schedule for the aged 7-18 years, and catch-up vaccination schedule for the age of 4 months to 18 years). (Editor’s note: In Germany, the vaccination recommendations by the Standing Committee on Vaccination at the Robert Koch Institute, STIKO be published.) The vaccination status should be checked at every visit. The current recommendations can on www.cdc.gov/vaccines/ (Editor’s note .: In Germany the recommendation of STIKO applies:.. Www.rki.de) can be viewed and are known as “free mobile app” available. For information on risks and side effects and information on the administration of specific vaccines s. Immunization (immunization). Recommended vaccination schedule for the age of 0-6 years vaccines Birth 1 month 2 months 4 months 6 months 9 months 12 months 15 months 18 months 19-23 months 2-3 years 4-6 years Hepatitis B (HepB) a first dose 2 . dose * 3rd dose * Rotavirus (RV) b 1st dose 2nd dose See footnote b Diphtheria-Tetanus-Pertussis (DTaP, <7 years) c 1st dose 2nd dose 3rd dose * 4. Dose * 5. dose Haemophilus influenzae type b conjugate vaccine (Hib) d 1st dose 2nd dose See footnote d * 3rd or 4th Dosisd * † pneumococcal conjugate vaccine (PCV13) e 1st dose 2nd dose 3 . dose * 4th dose * † Inactivated polio virus (IPV) for the first dose second dose third dose * 4th dose influenza (inactivated influenza vaccine [IIA] or alive-attenuated influenza vaccine [LAIV]) g Annual ( IIA) Annual (IIA or LAIV) Measles, mumps and rubella (MMR) h first dose * 2nd dose Varicella (VAR) i * 1st dose 2nd dose Hepatitis A (HEPA) j 2-dose Seriej ‡ meningococcal conjugate vaccine (Hib-Men-CY, MenACWY-D and CRM-MenACWY) k † See footnote k † pneumococcal polysaccharide vaccine (PPSV23) e †? = Recommended age limit for all children except for certain high-risk groups. * = Recommended age limit for post-immunization. † = bandwidth of the recommended ages for certain high-risk groups. ‡ = bandwidth of the recommended age for catching up and for certain high-risk groups. This schedule includes recommendations with effect from 1 February 2016. A dose is not administered within the recommended age should be administered at a subsequent visit when indicated and feasible. The use of a combination vaccine is preferred generally separate injections of equivalent vaccine components. Considerations should include an evaluation of the provider, patient preference and potential side effects. Providers should the appropriate ACIP statement for detailed recommendations consult with http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) under http://www.vaers.hhs.gov or by telephone, 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to state or local health department. If children were not vaccinated or even incomplete, a timetable should be set up to make up for vaccinations. For calculation of the intervals between doses 4 weeks = 28 days. Intervals of ? 4 months are determined by calendar months. For more information on vaccine requirements on trip nfinden on the website of the CDC For Travelers. aHepatitis B (HepB) Vaccine. The minimum age is shortly after birth. At birth: administering monovalent HepB to all newborns before they are discharged from hospital. When the nut for hepatitis B surface antigen (HBsAg) is positive, HepB and 0.5 ml of hepatitis B immunoglobulin (HBIG) should be administered after birth within 12 h. These infants should be tested at the age of 9-18 months HBsAg antibody (anti-HBs) (best at screening) or 1-2 months after completion of the hepatitis B series. The Centers for Disease Control and Prevention (CDC) have recently recommended that the tests are to be performed at the age of 9-12 months (Update: Shortened Interval for Postvaccination serologic testing of Infants Born to Hepatitis B Infected Mothers). If the maternal HBsAg status is unknown, the HepB vaccine is administered within 12 hours after birth all infants, regardless of birth weight. If infants weighing <2000 g, HBIG is administered in addition to the HepB vaccine within 12 hours after birth. The HBsAg status of the mother should be determined as soon as possible. If it proves to be positive, babies should weigh the ? 2000 g, HBIG are administered (not later than 7 days after birth). Dose after birth: The second dose should be administered at the age of 1-2 months. Monovalent HepB vaccine should be used for gifts before the age of 6 weeks. A total of 4 doses of the HepB vaccine is permitted if a combination vaccine with HepB after birth dose was given. Infants who have not received a birth dose should receive 3 doses of HepB-containing vaccine in a schedule of 0 months, 1-2 months and 6 months, as soon as possible (see table: catch-up vaccination schedule for the age of 4 months to 18 years). The minimum distance 1 to 2 dose is 4 weeks and 2 to 3 doses 8 weeks. The final (3rd or 4th) dose of HepB vaccine series should not be given before the age of 24 weeks and 16 weeks after the first dose. bRotavirus- (RV) vaccines Minimum 6 weeks RV-1 (Rotarix ®) and RV-5 (RotaTeq®). When RV-1 (Rotarix ®) is used, 2 doses are administered: the age of 2 months and 4 months. When RV-5 (RotaTeq®) is used, 3 doses are administered: the age of 2 months, 4 months and 6 months. If any dose in a series RV-5 (RotaTeq®) was or is unknown, 3 doses should be administered. The maximum age is at 14 weeks and 6 days for the first dose in the series and 8 months, and 0 days for the final dose in the series. Vaccination should not be initiated for infants aged 15 weeks and 0 days or older. When RV-1 (Rotarix®) was administered for the first and second doses, a third dose is not displayed. cDiphtherie- and tetanus toxoid and pertussis acellular (DTaP) vaccine. The minimum age is 6 weeks, with the exception of DTaP-IPV (Kinrix®), which has a minimum age of 4 years. Enter a 5-dose DTaP series at the age of 2, 4, 6, 15-18 Mo and 4-6 years. The fourth dose may be given as early as age 12 months, provided that at least 6 months have elapsed since the third dose. If the fourth dose is administered at least 4 months but <6 months after the third dose, they need not be repeated. A fifth dose of DTaP is not necessary if the fourth dose was administered at age ? 4 years dHaemophilus influenzae type b (Hib) conjugate vaccine. The minimum age is 6 weeks for PRP-T (ActHIB®, DTaP-IPV / Hib [Pentacel®] and Hib MenCY [MenHibrix®]) and PRP-OMP (PedvaxHIB® or COMVAX®) and 12 months for PRP-T ( Hiberix®). It is a primary series of 2 or 3 doses of the Hib vaccine with a booster dose administered (dose 3 or 4 depending on the vaccine, which was used in the primary immunization) aged 12 to 15 months to complete Hib series to to complete. The primary series consists of PRP-T with 3 doses to be administered at the age of 2, 4 and 6 months, and for PRP-OMP of 2 doses administered at age 2 and 4 months. If PRP-OMP (PedvaxHIB® or ComVax® [Hib-HepB]) is given at the age of 2 and 4 months, another dose at age 6 months is not indicated. A booster dose (dose 3 or 4 depending on the vaccine, which was used in the primary immunization) should be administered at the age of 12 to 15 months. An exception is Hiberix® that only for the booster dose (last dose) should be used in children aged 12 months to 4 years who have received at least 1 dose of Hib. The Hib vaccine is not administered> 5 years routinely patients. However, 1 dose of non-immunized patients, aged ? 5 years should be administered, if they have an anatomical or functional Asplenie (including sickle cell disease) and non-vaccinated patients aged 5-8 years with HIV infection. Patients are considered to be non-immunized if they have not received a primary series and booster dose or at least 1 dose of Hib vaccine after the age of 14 months. Only one dose is administered unvaccinated children aged ? 15 months. For other catch-up recommendations, see table: catch-up vaccination schedule for the age of 4 months to 18 years. In the following recommendations for children are given with an increased risk of Hib infection: If children aged 12-59 months at increased risk for Hib infection have (including chemotherapy recipients and those with anatomic or functional asplenia [eg. came with sickle cell disease], HIV infection, immunoglobulin deficiency or early component complement deficiency) and no cans or only one dose of the Hib vaccine before the age of 12 months, they should be two additional doses of Hib vaccine 8 weeks apart, preserved. Kids who ? 2 doses of Hib vaccine were given before the age of 12 months should receive one additional dose. If patients <5 years old and receiving chemotherapy or radiation therapy, ? 1 Hib vaccine dose was given within 14 days of starting therapy or during therapy should the doses at least 3 months after the treatment was completed, be repeated. The recipient of a hematopoietic stem cell should be refreshed at a 3-fold dose of Hib vaccine, beginning 6-12 months after the successful transplantation, regardless of previous vaccinations; Doses should be given at least 4 weeks apart. contains a single dose of each vaccine, Hib, unimmunized children and adolescents ? 15 months should be given if they had an elective splenectomy; if possible, the vaccine should be given at least 14 days before the procedure. ePneumokokken vaccines. The minimum amounts to 6 weeks for the 13-valent pneumococcal conjugate vaccine (PCV13) and 2 years for the 23-valent pneumococcal polysaccharide vaccine (PPSV23). A dose PCV13 should be administered to all healthy children aged 24-59 months who are not fully immunized according to their age. All children aged 14 to 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), an additional single dose of PCV13 is administered. Children aged from 2 to 5 years of medical findings 1 dose is administered PCV13 when 3 doses of PCV (PCV7 and / or PCV13) was added previously. Otherwise 2 doses of PCV with a minimum of 8 weeks can be administered when the child previously <3 doses of PCV (PCV7 and / or PCV13) received. One additional dose of PCV13 is given to children who received 4 doses of PCV7 or other age-appropriate PCV7 series have been completed. If children have had (including cochlear implant) either PCV13 still PPSV23 aged 6 to 18 years old with certain medical conditions, one dose of PCV13, followed by one dose is PPSV23 at least 8 weeks later, administered (see p. 59 MMWR [RR 11]: 1-19, 2010, available on http://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf). Administration of PPSV23 at least 8 weeks after the last dose of PCV13 for children aged ? 2 years with certain medical conditions, including a cochlear implant is indicated. A single revaccination with PPSV23 should be administered with anatomic or functional asplenia or an immunosuppressive condition 5 years after the first dose to children. fInaktivierter polio vaccine (IPV). The minimum age is 6 weeks. Prescribe a 4-dose IPV series at the age of 2, 4, 6-18 months, and 4-6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the last dose. During the first 6 months of life, minimum age and minimum distances are recommended only if the child is in immediate danger of exposure to circulating poliovirus, for example. B. on the journey to a polio-endemic country during an outbreak. When administered before the age of 4 years ? 4 doses, an additional dose at age 4 to 6 years and at least 6 months should'll administered after the last dose. A fourth dose is not necessary if the third dose at age ? 4 years and at least 6 months was administered after the last dose. If both the oral polio vaccine (OPV) and IPV were given as part of a series, a total of 4 doses should be given, regardless of the current age of the child. If only given the OPC, and all doses were given before the age of 4 years, a dose of IPV at age ? 4 years and 4 weeks should be administered after the last OPV dose. gInfluenza vaccine (seasonal). Minimum age is 6 months for inactivated influenza vaccine (IIA) and 2 years for live-attenuated influenza vaccine (LAIV). In most healthy children aged ? 2 years, either LAIV or IIV can be used. However, LAIV should some children not be given, including children with asthma, children aged 2 to 4 years who had wheezing in the last 12 months, and children who have any other medical finding, which predisposes them to influenza complications. For all other contraindications for the use of LAIV, s. MMWR 62 (RR-7), 1-43, 2013, available on http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm. For children aged 6 months to 18 years of age: ? In the season 2015/16 are children who get the influenza vaccine for the first time, two doses administered (at a distance of at least 4 weeks). Some children who have previously been vaccinated, also need two doses. For further instructions, s. the dosage guidelines in the 2015-16 ACIP recommendation for the influenza vaccine in MMWR 64 (30): 818-25, 2015, available on http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm. ? For more information, see influenza vaccination recommendations ACIP (available on http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html). gInfluenza vaccine (seasonal). Minimum age is 6 months for inactivated influenza vaccine (IIA) and 2 years for live-attenuated influenza vaccine (LAIV). In most healthy children aged ? 2 years, either LAIV or IIV can be used. However, LAIV should some children not be given, including children with asthma, children aged 2 to 4 years who had wheezing in the last 12 months, and children who have any other medical finding, which predisposes them to influenza complications. For all other contraindications for the use of LAIV, s. MMWR 62 (RR-7), 1-43, 2013, available on http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm. For children aged 6 months to 18 years of age: ? In the season 2015/16 are children who get the influenza vaccine for the first time, two doses administered (at a distance of at least 4 weeks). Some children who have previously been vaccinated, also need two doses. For further instructions, s. the dosage guidelines in the 2013-14 ACIP recommendation for the influenza vaccine in MMWR 64 (30): 818-25, 2015, available on http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm. ? For more information, see ACIP recommendations for the influenza vaccine (available on http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html). hMasern-mumps-rubella (MMR) vaccine. The minimum age is 12 months, the second dose can be administered before the age of 4 years, provided that at least four weeks have passed since the first dose. Infants aged 6-11 months traveling internationally, 1 dose of MMR vaccine is administered. These children should be revaccinated with two doses of MMR vaccine: the first dose at age 12 to 15 months (at the age of 12 months, if the child remains in a high-risk region) and the second dose at least 4 weeks after the previous dose children aged ? 12 months that travel internationally are administered 2 doses of the MMR vaccine; The first dose is given from the age of 12 months and the second dose at least 4 weeks after the previous dose. iVaricella- (VAR) vaccine. The minimum age is 12 months, the second dose can be administered before the age of 4 years, provided that at least 3 months have passed since the first dose. If the second dose was administered at least 4 weeks after the first dose, the vaccine may also be accepted as valid. jHepatitis-A- (HepA) vaccine. The minimum age of 12 months The second (last) dose is administered 6 to 18 months after the first dose. When children have received one dose of HepA before the age of 24 months, a second dose 6 to 18 months after the first dose is administered. Unvaccinated children who are at high risk or who live in areas where vaccination programs targeting the older children should be vaccinated. S. MMWR 55 [RR-7], 2006 (available on www.cdc.gov/mmwr/pdf/rr/rr5507.pdf) and additional information available on http://www.cdc.gov/vaccines/hcp/acip -recs / VACC-specific / hepa.html. A HepA vaccine series of two doses is recommended for all persons aged ? 2 years if they have not been vaccinated before and if an immunity to hepatitis A is desirable for them. kMeningokokken conjugate vaccines, quadrivalent. The minimum is due 6 weeks for Hib-MenCY (MenHibrix®; for H. influenzae type b and Neisseria meningitidis serogroups C and Y), 9 months for MenACWY-D (Menactra®), 2 months for Menveo (Menveo®) and 10 years for serogroup B meningococcus (MenB) vaccinations (Men B-4c [Bexsero®] MenB FHBP [Trumenbal®]). Children aged 2 to 18 months, (D including patients with inherited chronic deficiencies of C3, C5 -C9, properdin, Factor or Factor H and those Eculizumab occupy) a persistent Komplementkomponentenmangel or an anatomical or functional Asplenie (including sickle cell anemia have), 6 and 12 months, a 4-dose infant series of Hib MenCYim the age of 2, 4, 6, and 12 -15 months or CRM-MenACWY at the age of 2, 4, administered. For children aged 7 to 23 months who have a persistent Komplementkomponentenmangel and have taken no vaccination, there are two possibilities. CRM-MenACWY can be given at age 7 to 23 months in a series of 2 doses at which the 2nd dose after the age of 12 months and at least 12 weeks after the first dose is given. Or MenACWY-D can be given at age 9 to 23 months in a series of 2 doses, at doses at least 12 weeks apart. Children aged 19 to 23 months, which have an anatomical or functional Asplenie and which have not been fully immunized with Hib-MenCY or CRM-MenACWY, 2 primary doses of CRM-MenACWY be administered at intervals of at least 12 weeks. Children aged ? 24 months who have a persistent Komplementkomponentenmangel or an anatomical or functional Asplenie and which have not been fully vaccinated, 2 doses of the primary MenACWY-D or CRM-MenACWY vaccine to be administered at intervals of at least 8 weeks. If MenACWY-D is used in children with anatomic or functional asplenia, vaccination in a minimum of 2 years and at least 4 weeks after the completion of all PCV13 doses should be. If children live with a high-risk findings in a country where meningococcal disease is hyper endemic or epidemic, or to such countries traveling (eg. As the African meningitis belt, the Hajj), are age-appropriate formulations and series of MenACWY-D or Menveo administered to protect against serogroups A and W. A previous vaccination with Hib MenCY is not sufficient for children traveling in these regions (see MMWR 62 (RR2): 1-22, 2013; available on http://www.cdc.gov/mmwr/preview/mmwrhtml. /rr6202a1.htm). When children are present with a high-risk findings during outbreaks of a vaccine serogroup, an age- and formulation just series of Hib-MenCY, MenACWY-D, CRM-MenACWY, MenB-4C or MenB FHBP is administered or completed. If children with a high-risk findings received their first dose of Hib MenCY from the age of 12 months, a total of two doses are administered at intervals of at least 8 weeks to ensure protection against serogroups C and Y meningococcal disease. If children with a high-risk findings received their first dose of Menveo at age 7 and 9 months, a series of 2 doses, in which the second dose after the age of 12 months and at least 3 months after the first dose is optionally administered. When the patients have a persistent Komplementkomponentenmangel or an anatomical or functional Asplenie and did not have complete meningococcal vaccination series, they are given at intervals of at least 1 month or 3 doses of Men B-FHBP vaccine 2 doses of Men B-4c vaccine with the second dose at intervals of at least 2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; The same vaccine product must be used for all doses. For further instructions, including guidelines for revaccination, s. MMWR 62 (RR2): 1-22, 2013 (available on http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm) 64, MMWR (41): 1171-76.2015 (available at http : //www.cdc.gov/mmwr/pdf/wk/mm6441.pdf) and meningococcal vaccine ACIP recommendations (available on http://www.cdc.gov/vaccines/hcp/acip-recs/vacc- specific / mening.html). ACIP = Advisory Committee on Immunization Practices; MMWR Morbidity and Mortality Weekly Review =; PRP-OMP = Neisseria meningitidis polyribosylribitol phosphate / outer membrane protein. Adapted from Centers for Disease Control and Prevention: Recommended Immunization Schedule for Persons Aged 7 Through 18 Years, United States, 2016. Available at: http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html. Recommended vaccination schedule for the age of 7-18 years vaccines 7-10 years 11-12 years 13-18 years Hepatitis B (HepB) a * Complete series of 3 doses of Haemophilus influenzae type b conjugate vaccine (Hib) b † See footnote b , Pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) † c See footnote c. Inactivated poliovirus (IPV) d * See footnote d. Influenzae annually (IIA or L

Health Life Media Team

Leave a Reply